@truss20 thank you for the articulated post. I agree with your analysis of the MSB announcement in that it doesn’t get in the way (at least immediately) of Cynata’s pursued GVHD indication. However if MSB executives were truly “petrified” of CYP, then they could move to acquire it.
In full disclosure, I am long MSB and sold all my shares in CYP yesterday with effectively no loses. I will be closely monitoring to see how the market responds. Perhaps this will represents a near term buying opportunity in the low teens.
VFM
Why Orphan Drug Designation for mesoblast is IRRELEVANT to Cynata, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $10.82K | 65.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4450 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 88474 | 2 |
View Market Depth
| Last trade - 15.32pm 20/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |